Unilever, McCormick strike deal to create $65 billion food giant

Unilever will spin off its food unit and merge it with McCormick in a $65 billion deal, Unilever will own 65%, get $15.7 billion cash; shares in both firms fell

Unilever will spin off its food unit and merge it with McCormick in a $65 billion deal, Unilever will own 65%, get $15.7 billion cash; shares in both firms fell

The deal values Nxtra at $3.1 billion and is aimed at accelerating its expansion across India. The company plans to scale up its capacity from around 300MW currently to 1GW over the next few years, targeting a 25% market share.

According to brokerage firm Jefferies, the moves announced by the RBI could result in a smoother transition for brokers / proprietary traders, as bank guarantees can now be renewed for up to a year.

Even as history is in favour of the bulls going into the April series, the biggest trigger for any form of reversal from near 52-week lows will be a de-escalation in the US-Iran war and a subsequent drop in oil…

The big move upwards on Tuesday came after Iran’s news agency cited a call between President Masoud Pezeshkian and European Union Council President Antonio Costa, where Pezeshkian said that Iran has the will to end the war, but only with…

Buffett flags inflation, banking risks, criticises speculation, stays heavy on cash, cautious on markets, and says geopolitical tensions and nuclear threats add to global uncertainty.

Nifty’s short-term trend remains weak, as it continues to trade below key moving averages and the March 23 swing low of 22,471.

As the Iran war intensifies, President Donald Trump has prioritised efforts to calm the financial markets — trying to keep oil prices from exploding upward, stocks from cratering and interest rates from surging.

Airtel injects 1 billion dollars into Nxtra, major deals span copper, rail, energy storage, pharma and finance, MakeMyTrip hit by short seller report

Novo Nordisk on Tuesday cut the prices of its diabetes and weight-loss drugs Ozempic and Wegovy by as much as 36% and 48% in India, its second such move, to fend off competition from local drugmakers’ cheaper generics.